MEDICAL TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
https://doi.org/10.38109/2225-1685-2014-1-113-118
Abstract
CTEPH is the only type of surgically curable pulmonary arterial hypertension. In spite that, up to 50% of all CTEPH patients are rejected of surgical treatment because of distal lesions of pulmonary arteries or because of other contraindications. Medical treatment was proven to be one of the options to support this cohort of patients. Recent clinical studies addressed some medication regimens for treatment of CTEPH patients and showed distinct changes of different PH-variables with time. We discuss the main principles of drug therapy for inoperable CTEPH as well as for patients awaiting surgery, during and after pulmonary thrombo-endarterectomy.
About the Authors
K. V. Mershin
Institute of clinical cardiology, Russian cardiology research complex
Russian Federation
Russian Federation
T. V. Martynuk
Institute of clinical cardiology, Russian cardiology research complex
Russian Federation
Russian Federation
References
1. Матюшенко А.А. Хроническая постэмболическая легочная гипертензия. 50 лекций по хирургии. М: Медиа Медика 2003; 99-105.
2. Чернявский А.М., Альсов С.А., Аляпкина Е.М. Первый опыт хирургического лечения хронической тромбоэмболии легочной артерии. Дальневосточный мед. журн. 2007:2; 63-65.
3. Чернявский А.М., Аляпкина Е.М., Чернявский М.А. и др. Изменения гемодинамических показателей малого круга кровообращения у пациентов с хронической постэмболической легочной гипертензией после операции тромбэндартерэктомии из ветвей легочной артерии. Кардиология и сердечно-сосудистая хирургия 2013; 1:76-80.
4. Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, et al. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest 2006;130:172-5.
5. Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2599- 2603.
6. Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009; 33:325-31.
7. Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004; 23: 595-600.
8. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, et al. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009; 33: 332-8.
9. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493-2537.
10. Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005; 128:2363-7.
11. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006; 113:2011-20.
12. Jensen KW, Kerr KM, Fedullo PF, Kim NH, Test VJ, Ben-Yehuda O, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120: 1248-54.
13. Kunieda T, Nakanishi N, Satoh T et al. Prognoses of Primary pulmonary Hypertension and chronic major vessel thromboembolic pulmonary hypertension determined from cumulative survival curves. Intern Med 1999; 38:543-546.
14. Lang IM. Chronic thromboembolic pulmonary hypertension -not so rare after all. N Engl J Med 2004;350:2236-8.
15. Lewczuk J, Piszko P, Jagas J et al. Prognostic factors in medically treated patients with chronic pulmonary embolism. Chest 2001; 119:818-823.
16. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123:338-43.
17. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004; 350: 2257-64.
18. Reesink HJ, Surie S, Kloek JJ, Tan HL, Tepaske R, Fedullo PF, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg. 2009;139:85-91.
19. Reichenberger F, Voswinckel R, Enke B, et al. Longterm treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30:922-7.
20. Seyfarth H.J., Halank M, Wilkens H, Schaefers HJ, Ewert R, Riedel M, Schuster E. Hammerschmidt S, Wirtz H. Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol 2010;99:553-6.
21. Wilkens H, Lang I, Behr J et al. Chronic thromboembolic pulmonary hypertension (CTEPH): Updated Recommendations of the Cologne Consensus Conference International Journal of Cardiology 2011; 152S: S54-S60
Review
For citations:
Mershin K.V., Martynuk T.V. MEDICAL TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Eurasian heart journal. 2014;(1):113-118. (In Russ.) https://doi.org/10.38109/2225-1685-2014-1-113-118
Views:
363
Email this article 
